Angelini Pharma Announces Appointment of Sergio Marullo di Condojanni as New CEO

Contributed by: GlobeNewswire

Tags

Brain health

More Like This

Angelini Pharma Signs Exclusive Option Agreement With Sovargen To License Global Development and Commercialization Rights For Innovative Brain Health Asset

Angelini Pharma and Quiver Bioscience Announce Strategic Research Collaboration and Licensing Agreement to Discover and Advance Novel Therapeutics for Genetic Epilepsies

PR Newswire associated0

MENARINI GROUP: THOMAS CUENI APPOINTED NEW MEMBER OF THE BOARD

Angelini Pharma Enters Into An Exclusive Option Agreement With Cureverse to License Global Development and Commercialization Rights For A Novel and Innovative Clinical-Stage Brain Health Asset

PR Newswire associated0

The Ferrero Group announces new governance and leadership roles, reporting into Giovanni Ferrero, President of Ferrero International S.A.

BeiGene Announces Appointment of Giancarlo Benelli as Head of Europe

Topflight Pharma Development Veteran Joins Synendos

Maria Paola Chiesi is appointed Chair of Chiesi Board of Directors, the first woman in this role; aims to reinforce sustainability as an integral and enduring pillar of the Group’s strategy

Chiesi Group Announces New Chair and Vice Chair